New insights into the pathophysiology of dyslipidemia in type 2 diabetes
2015/02/07 by Marja-Riitta Taskinen, Marja‐Riitta Taskinen, Jan Borén · 28 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Diabetes, Cardiovascular Risks, and Lipoproteins #Lipid metabolism and disorders #Cancer, Lipids, and Metabolism
paper · doi:10.1016/j.atherosclerosis.2015.01.039
Citations
Cited by
- Evidence for increased chylomicron remnants in rheumatoid arthritis
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy? [europepmc]
- Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease? [europepmc]
- TM6SF2 rs58542926 impacts lipid processing in liver and small intestine. [europepmc]
- PPARβ/δ: A Key Therapeutic Target in Metabolic Disorders. [europepmc]
- Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. [europepmc]
- Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. [europepmc]
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. [europepmc]
- Serum Lipid Profile and Its Association with Diabetes and Prediabetes in a Rural Bangladeshi Population. [europepmc]
- Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. [europepmc]
- Human PAH is characterized by a pattern of lipid-related insulin resistance. [europepmc]
- Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD. [europepmc]
- Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I. [europepmc]
- Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. [europepmc]
- The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. [europepmc]
- Current Data Regarding the Relationship between Type 2 Diabetes Mellitus and Cardiovascular Risk Factors. [europepmc]
- Causes and Consequences of Hypertriglyceridemia. [europepmc]
- Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue. [europepmc]
- The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans. [europepmc]
- A Comprehensive Update on the Chylomicronemia Syndrome. [europepmc]
- The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. [europepmc]
- Dietary Regulation of Oxidative Stress in Chronic Metabolic Diseases. [europepmc]
- Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. [europepmc]
- Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes: Findings From the ACCORD Cohort. [europepmc]
- Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. [europepmc]
- Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia. [europepmc]